Vernakalant: Pharmacology, electrophysiology, safety and efficacy

Gerald V. Naccarelli, Deborah L. Wolbrette, Soraya Samii, Javier E. Banchs, Erica Penny-Peterson, Robert Stevenson, Mario D. Gonzalez

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

The development of new antiarrhythmic agents for the treatment of atrial fibrillation is advancing simultaneously on several fronts. The molecular structure of existing agents such as amiodarone is being modified in an attempt to improve safety and reduce adverse effects. Similarly, atrial-selective antiarrhythmic drugs are being developed to minimize the occurrence of ventricular proarrhythmia. One of these atrial-selective compounds is vernakalant, which has demonstrated efficacy in terminating atrial fibrillation when given intravenously. In addition, preliminary data suggest that it could also suppress recurrences when used orally. This paper reviews the pharmacology, electrophysiology, efficacy and safety of intravenous and oral vernakalant.

Original languageEnglish (US)
Pages (from-to)325-329
Number of pages5
JournalDrugs of Today
Volume44
Issue number5
DOIs
StatePublished - May 1 2008

Fingerprint

Electrophysiology
Atrial Fibrillation
Pharmacology
Safety
Amiodarone
Anti-Arrhythmia Agents
Molecular Structure
Recurrence
vernakalant

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Naccarelli, Gerald V. ; Wolbrette, Deborah L. ; Samii, Soraya ; Banchs, Javier E. ; Penny-Peterson, Erica ; Stevenson, Robert ; Gonzalez, Mario D. / Vernakalant : Pharmacology, electrophysiology, safety and efficacy. In: Drugs of Today. 2008 ; Vol. 44, No. 5. pp. 325-329.
@article{ae0b86abc06e4524b129e6ca66a619a3,
title = "Vernakalant: Pharmacology, electrophysiology, safety and efficacy",
abstract = "The development of new antiarrhythmic agents for the treatment of atrial fibrillation is advancing simultaneously on several fronts. The molecular structure of existing agents such as amiodarone is being modified in an attempt to improve safety and reduce adverse effects. Similarly, atrial-selective antiarrhythmic drugs are being developed to minimize the occurrence of ventricular proarrhythmia. One of these atrial-selective compounds is vernakalant, which has demonstrated efficacy in terminating atrial fibrillation when given intravenously. In addition, preliminary data suggest that it could also suppress recurrences when used orally. This paper reviews the pharmacology, electrophysiology, efficacy and safety of intravenous and oral vernakalant.",
author = "Naccarelli, {Gerald V.} and Wolbrette, {Deborah L.} and Soraya Samii and Banchs, {Javier E.} and Erica Penny-Peterson and Robert Stevenson and Gonzalez, {Mario D.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1358/dot.2008.44.5.1216597",
language = "English (US)",
volume = "44",
pages = "325--329",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "5",

}

Vernakalant : Pharmacology, electrophysiology, safety and efficacy. / Naccarelli, Gerald V.; Wolbrette, Deborah L.; Samii, Soraya; Banchs, Javier E.; Penny-Peterson, Erica; Stevenson, Robert; Gonzalez, Mario D.

In: Drugs of Today, Vol. 44, No. 5, 01.05.2008, p. 325-329.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Vernakalant

T2 - Pharmacology, electrophysiology, safety and efficacy

AU - Naccarelli, Gerald V.

AU - Wolbrette, Deborah L.

AU - Samii, Soraya

AU - Banchs, Javier E.

AU - Penny-Peterson, Erica

AU - Stevenson, Robert

AU - Gonzalez, Mario D.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - The development of new antiarrhythmic agents for the treatment of atrial fibrillation is advancing simultaneously on several fronts. The molecular structure of existing agents such as amiodarone is being modified in an attempt to improve safety and reduce adverse effects. Similarly, atrial-selective antiarrhythmic drugs are being developed to minimize the occurrence of ventricular proarrhythmia. One of these atrial-selective compounds is vernakalant, which has demonstrated efficacy in terminating atrial fibrillation when given intravenously. In addition, preliminary data suggest that it could also suppress recurrences when used orally. This paper reviews the pharmacology, electrophysiology, efficacy and safety of intravenous and oral vernakalant.

AB - The development of new antiarrhythmic agents for the treatment of atrial fibrillation is advancing simultaneously on several fronts. The molecular structure of existing agents such as amiodarone is being modified in an attempt to improve safety and reduce adverse effects. Similarly, atrial-selective antiarrhythmic drugs are being developed to minimize the occurrence of ventricular proarrhythmia. One of these atrial-selective compounds is vernakalant, which has demonstrated efficacy in terminating atrial fibrillation when given intravenously. In addition, preliminary data suggest that it could also suppress recurrences when used orally. This paper reviews the pharmacology, electrophysiology, efficacy and safety of intravenous and oral vernakalant.

UR - http://www.scopus.com/inward/record.url?scp=51649104101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649104101&partnerID=8YFLogxK

U2 - 10.1358/dot.2008.44.5.1216597

DO - 10.1358/dot.2008.44.5.1216597

M3 - Review article

C2 - 18548135

AN - SCOPUS:51649104101

VL - 44

SP - 325

EP - 329

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 5

ER -